Tokyo, Aug. 27 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058897) titled 'A placebo-controlled randomized double-blind parallel-group comparison study on the effects of continued intake of collagen peptides on the skin and scalp' on Aug. 27.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - Miura Clinic, Medical Corporation Kanonkai

Condition: Condition - Healthy Adult Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Evaluate the effects on skin and scalp by continuously ingestion of test food for 12 weeks Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Intake of test food for 12 consecutive weeks Interventions/Control_2 - Intake of control placebo food for 12 consecutive weeks

Eligibility: Age-lower limit - 20 years-old = Gender - Male and Female Key inclusion criteria - (1) Healthy men and women aged 20 to 64 (2) Individuals with dry skin and scalp (3) Individuals who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing Key exclusion criteria - (1) Individuals with a history of mental illness, diabetes, liver disease, renal diseases, gastrointestinal disease, cardiac disease, respiratory disease, peripheral vascular disease, or other serious disease.

(2) Individuals who have undergone gastrointestinal surgery. (3) Individuals showing abnormal liver and kidney function test values. (4) Individualswith a current medical condition. (5) Individuals with skin symptoms. (6) Individuals who are allergic to food and drugs. (7) Individuals with symptoms of anemia. (8) Females wishing to become pregnant while participating in this study, pregnant (including those who may be pregnant) or lactating female subjects. (9) Individuals who participate in strenuous sports and subjects who are trying to lose weight. (10) Individuals with extremely irregular eating habits. (11) Individuals who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the study period. (12) Individuals who are continuously treated with medications (including OTC, prescription drugs). (13) Individuals who drink more than 40 g of average daily pure alcohol. (14) Individuals who smoke an average of 21 or more cigarettes a day. (15) Individuals who are currently participating in other clinical studies or are scheduled to participate in research at the start of this study. (16) Individuals judged by the principal investigator or the associate investigator to be inappropriate for the examination. Target Size - 60

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 08 Month 20 Day Date of IRB - 2025 Year 08 Month 21 Day Anticipated trial start date - 2025 Year 08 Month 28 Day Last follow-up date - 2025 Year 12 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067341

Disclaimer: Curated by HT Syndication.